经导管主动脉瓣置换术治疗失败的外科生物瓣:STS/ACC注册研究
该研究基于STS/ACC注册数据,将1150例因外科主动脉瓣生物瓣失败行ViV-TAVR的患者与2259例原生瓣膜TAVR患者按1:2匹配,比较安全性和有效性。调整分析显示ViV-TAVR组30天死亡、1年死亡及心衰住院风险均更低,但术后平均跨瓣压差更高、中度以上主动脉瓣反流更少。结论提示对于再手术高风险患者,ViV-TAVR是安全有效的。
要点
- ViV-TAVR组调整后30天死亡风险低于NV-TAVR组(HR 0.503)。
- ViV-TAVR组1年死亡和心衰住院风险均低于NV-TAVR组。
- ViV-TAVR术后平均跨瓣压差更高,但中重度主动脉瓣反流更少。
核心结论
- 对于再手术高风险的外科主动脉瓣生物瓣失败患者,ViV-TAVR是安全有效的手术。
研究设计与样本
- 基于STS/ACC TVT注册的研究,ViV-TAVR组1150例与NV-TAVR组2259例按1:2匹配。
- 匹配因素包括性别、高风险或极高风险、胸廓畸形或瓷化主动脉、5米步行时间及再手术STS预测死亡风险。
- 基线特征、手术数据和院内结局来自TVT注册,30天和1年结局来自链接的Medicare行政索赔数据。
主要发现
- 未调整分析中,ViV-TAVR组较NV-TAVR组30天死亡率更低(2.9% vs. 4.8%;p < 0.001)。
- 未调整分析中,ViV-TAVR组较NV-TAVR组30天卒中率更低(1.7% vs. 3.0%;p = 0.003)。
- 未调整分析中,ViV-TAVR组较NV-TAVR组30天心衰住院率更低(2.4% vs. 4.6%;p < 0.001)。
- 调整分析显示ViV-TAVR组30天死亡风险更低(HR 0.503;95%CI 0.302-0.839;p = 0.008)。
- 调整分析显示ViV-TAVR组1年死亡风险更低(HR 0.653;95%CI 0.505-0.844;p = 0.001),心衰住院风险更低(HR 0.685;95%CI 0.500-0.939;p = 0.019)。
临床怎么用
- 对于外科生物瓣失败且再手术高风险的患者,可考虑ViV-TAVR。
- 需关注ViV-TAVR术后跨瓣压差升高,尤其在小尺寸或狭窄的外科瓣中。
局限性
- 30天和1年结局来自Medicare行政索赔数据,可能存在编码偏倚。
- 研究为观察性注册分析,即使经过匹配仍可能存在残余混杂。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Valve-in-valve (ViV) transcatheter aortic valve replacement (TAVR) has been shown to be feasible, yet the safety and efficacy in relation to native valve (NV) TAVR are not known. OBJECTIVES: This study sought to evaluate the safety and effectiveness of ViV TAVR for failed surgical aortic valve replacement (SAVR) by comparing it with the benchmark of NV TAVR. METHODS: Patients who underwent ViV-TAVR (n = 1,150) were matched 1:2 (on sex, high or extreme risk, hostile chest or porcelain aorta, 5-m-walk time, and Society of Thoracic Surgeons Predicted Risk of Mortality for reoperation) to patients undergoing NV-TAVR (n = 2,259). Baseline characteristics, procedural data, and in-hospital outcomes were obtained from the Transcatheter Valve Therapy Registry. The 30-day and 1-year outcomes were obtained from linked Medicare administrative claims data. RESULTS: Unadjusted analysis revealed lower 30-day mortality (2.9% vs. 4.8%; p < 0.001), stroke (1.7% vs. 3.0%; p = 0.003), and heart failure hospitalizations (2.4% vs. 4.6%; p < 0.001) in the ViV-TAVR compared with NV-TAVR group. Adjusted analysis revealed lower 30-day mortality (hazard ratio: 0.503; 95% confidence interval: 0.302 to 0.839; p = 0.008), lower 1-year mortality (hazard ratio: 0.653; 95% confidence interval: 0.505 to 0.844; p = 0.001), and hospitalization for heart failure (hazard ratio: 0.685; 95% confidence interval: 0.500 to 0.939; p = 0.019) in the ViV-TAVR group. Patients in the ViV-TAVR group had higher post-TAVR mean gradient (16 vs. 9 mm Hg; p < 0.001), but less moderate or severe aortic regurgitation (3.5% vs. 6.6%; p < 0.001). Post-TAVR gradients were highest in small SAVRs and stenotic SAVRs. CONCLUSIONS: Comparison with the benchmark NV-TAVR shows ViV-TAVR to be a safe and effective procedure in patients with failed SAVR who are at high risk for repeat surgery.
引用
- Tuzcu EM, Kapadia SR, Vemulapalli S, et al. Transcatheter Aortic Valve Replacement of Failed Surgically Implanted Bioprostheses: The STS/ACC Registry. J Am Coll Cardiol. 2018. PMID: 30025572. doi:10.1016/j.jacc.2018.04.074
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。